EPS for Ra Pharmaceuticals, Inc. (RARX) Expected At $-0.73

March 14, 2018 - By Hazel Jackson

 EPS for Ra Pharmaceuticals, Inc. (RARX) Expected At $ 0.73

Analysts expect Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to report $-0.73 EPS on March, 19.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.73 EPS. After having $-0.68 EPS previously, Ra Pharmaceuticals, Inc.’s analysts see 7.35 % EPS growth. The stock decreased 1.82% or $0.1327 during the last trading session, reaching $7.1473. About 71,518 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Coverage

Among 3 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ra Pharmaceuticals had 5 analyst reports since August 24, 2017 according to SRatingsIntel. As per Tuesday, September 26, the company rating was maintained by Jefferies. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, October 24 report. Credit Suisse maintained the stock with “Outperform” rating in Friday, November 10 report. The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) earned “Buy” rating by Jefferies on Thursday, August 24.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $221.76 million. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

More notable recent Ra Pharmaceuticals, Inc. (NASDAQ:RARX) news were published by: Streetinsider.com which released: “Ra Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/Share” on February 14, 2018, also Businesswire.com with their article: “Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in …” published on March 01, 2018, Streetinsider.com published: “Ra Pharmaceuticals (RARX) to Offer $50M of Common Stock” on February 13, 2018. More interesting news about Ra Pharmaceuticals, Inc. (NASDAQ:RARX) were released by: Businesswire.com and their article: “Ra Pharma Supports 11th Annual Rare Disease Day┬« and Joins Global Movement to …” published on February 28, 2018 as well as Valuewalk.com‘s news article titled: “Ra Pharmaceuticals, Inc. (RARX) and MabVax Therapeutics Holdings, Inc. (MBVX …” with publication date: March 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.